Myovant Sciences Equity 2025

Myovant Sciences Aktienanalyse

What does Myovant Sciences do?

Myovant Sciences Ltd. is a biotech company based in London that specializes in medications for women and men in various therapy areas. The company was founded in 2016 through the collaboration of Takeda Pharmaceutical and Roivant Sciences Ltd. After going public in 2016, Myovant is now listed on the NYSE. Myovant Sciences focuses on medications for the treatment of reproductive system disorders, hormone regulation, and urinary tract issues in aging individuals. The company is involved in research and development of new therapy options and currently has a pipeline of 5 projects focusing on the following indications: - Symptomatic uterine fibroids - Endometriosis - Prostate cancer - Reproductive disorders in women - Reproductive disorders in men A fibroid is a growth in the tissue of the uterus that often occurs in women of reproductive age and becomes symptomatic. Endometriosis is a chronic, painful condition where tissue that normally lines the uterus grows outside of it. Myovant can also offer treatment options for reproductive disorders in men. The founders of Myovant Sciences aim to improve patient care, especially for rare diseases that are often under-researched and lack effective treatment options. The company focuses on innovative technologies and customized solutions to differentiate themselves from other companies. This includes a focus on targeted therapy options tailored to specific patient groups. Myovant has embraced the motto "Don't become MVP (Most Valuable Player), become MVP - Medical Value Provider." The company works closely with clinics, universities, research institutions, and other companies in the industry to leverage the latest scientific developments and use them for the development of medical solutions for the market. Myovant offers a wide range of products, with a main focus on medications for women and men with severe reproductive system, hormone, and urinary tract disorders in aging individuals. An example of a product is Elagolix, which was developed in collaboration with Abbvie Inc. for the treatment of endometriosis-related pain in women. Myovant Sciences Ltd. is an innovative company with an ambitious goal of developing medications for patients suffering from reproductive system disorders, hormone regulation, and urinary tract issues in aging individuals. The company conducts research and development of products for specific indications in order to offer targeted therapy options for patients. Myovant works closely with numerous partners to develop innovative solutions for patients. Myovant Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Myovant Sciences's Equity

Myovant Sciences's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Myovant Sciences's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Myovant Sciences's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Myovant Sciences's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Myovant Sciences’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Myovant Sciences stock

What is the equity of Myovant Sciences this year?

Myovant Sciences has equity of -473.48 M USD this year.

What was the equity of Myovant Sciences compared to the previous year?

The equity of Myovant Sciences has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of Myovant Sciences?

A high equity is advantageous for investors of Myovant Sciences as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Myovant Sciences?

A low equity can be a risk for investors of Myovant Sciences, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Myovant Sciences affect the company?

An increase in equity of Myovant Sciences can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Myovant Sciences affect the company?

A reduction in equity of Myovant Sciences can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Myovant Sciences?

Some factors that can affect the equity of Myovant Sciences include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Myovant Sciences so important for investors?

The equity of Myovant Sciences is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Myovant Sciences take to change the equity?

To change equity, Myovant Sciences can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Myovant Sciences pay?

Over the past 12 months, Myovant Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Myovant Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Myovant Sciences?

The current dividend yield of Myovant Sciences is .

When does Myovant Sciences pay dividends?

Myovant Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Myovant Sciences?

Myovant Sciences paid dividends every year for the past 0 years.

What is the dividend of Myovant Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Myovant Sciences located?

Myovant Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Myovant Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Myovant Sciences from 2/10/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/10/2025.

When did Myovant Sciences pay the last dividend?

The last dividend was paid out on 2/10/2025.

What was the dividend of Myovant Sciences in the year 2024?

In the year 2024, Myovant Sciences distributed 0 USD as dividends.

In which currency does Myovant Sciences pay out the dividend?

The dividends of Myovant Sciences are distributed in USD.